Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LEAD Therapeutics
San Bruno, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
At the time of acquisition, LEAD Therapeutics had a promising oncology program, particularly with LT-673, a PARP inhibitor for genetically defined cancers. BioMarin planned to advance this program.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
BioMarin PharmaceuticalPappas VenturesProQuest InvestmentsMustang Ventures
Beyond the preview
Go deeper on LEAD Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LEAD Therapeutics.